Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Orthopedic oncology

Is Radiation Therapy Used for TGCT After Surgery? Risks

At a Glance

Radiation is not routine after TGCT surgery. External-beam radiation may be considered for diffuse, recurrent, or residual tumors, or tumors outside the joint, but possible joint stiffness, bone damage, and rare secondary cancer must be balanced against uncertain benefit in preventing recurrence.

Yes, external-beam radiation therapy is sometimes used after surgery for Tenosynovial Giant Cell Tumor (TGCT), but it is not a standard, first-line treatment for most patients [1][2]. While surgery (a synovectomy, which removes the joint lining) is the primary treatment for TGCT, your doctor might suggest radiation as an “adjuvant” (add-on) therapy if you have a high risk of the tumor returning [3]. Clinical guidelines generally reserve radiation for specific, challenging cases of diffuse TGCT rather than recommending it for routine use [4].

When is Radiation Therapy Considered?

TGCT is technically classified as an intermediate, locally aggressive neoplasm—meaning it is typically non-cancerous (benign) and does not spread to distant organs, but it can aggressively invade local joint tissues [5][6]. The diffuse type (D-TGCT) can be especially difficult to remove entirely [7].

Your care team might consider post-surgery radiation if:

  • The tumor repeatedly returns: For persistent, recurrent disease that is difficult to manage with surgery alone [1].
  • Surgery could not remove all the tumor: If the tumor was too deeply wrapped around nerves or blood vessels, leaving a positive margin (meaning microscopic tumor cells are found at the edge of the removed tissue) or an incomplete resection [8][9].
  • The tumor extends outside the joint: Extra-articular invasion, meaning the tumor has grown beyond the joint capsule (such as into the back of the knee), makes it much harder to completely clear surgically [10].

The goal of radiation is to improve local tumor control and reduce the risk of the TGCT coming back. Some observational studies show that adding radiation can lower the recurrence rate for diffuse TGCT compared to surgery alone, though the evidence is considered very low-quality and outcomes vary significantly [11][12].

Balancing the Benefits and Risks

Because TGCT is a non-malignant tumor, doctors are extremely cautious about using treatments that can cause permanent side effects [13]. The likelihood of complications depends heavily on the dose, the specific joint, your prior surgeries, and your age. Risks include:

  • Common short-term effects (Skin changes and stiffness): Radiation can cause skin thickening or mild discoloration [14][8]. It also increases the risk of arthrofibrosis (thick scar tissue in the joint), leading to lasting stiffness [14]. Stiffness is a very common side effect of the surgery itself, but radiation can make it worse [15][16].
  • Uncommon late effects (Bone health issues): Depending on the dose, radiation can weaken the bone over time, potentially leading to osteonecrosis (bone death) or fractures. This is less common at the lower radiation doses typically used for TGCT [14].
  • Rare but serious risks (Secondary malignancies): There is a recognized, though very rare, risk that radiation can cause healthy cells to mutate into a high-grade, cancerous sarcoma years or decades later [13][14]. While clinical studies tracking TGCT patients who received radiation have generally not observed these cancers, the follow-up periods are often too short to capture this late risk completely [17]. This theoretical but serious risk is why radiation is used sparingly, particularly in young, active patients [18].

Other Treatment Options

If you have residual tumor or are at high risk for recurrence, radiation is not the only option. A multidisciplinary tumor board (a group of orthopedic oncologists, radiation oncologists, and medical oncologists reviewing your case together) might recommend alternatives to radiation:

  • Active Surveillance: If a small amount of tumor was left behind but you have no symptoms, your doctor might recommend active surveillance. This is not simply “doing nothing”—it is a planned strategy of monitoring the joint with regular MRIs, clinical exams, and symptom checks (like pain or loss of motion) to see if the tumor actually grows or causes issues before trying more treatments [6].
  • Systemic Therapies (CSF1R Inhibitors): Drugs like pexidartinib and vimseltinib are FDA-approved targeted therapies (pills) for TGCT [19][20]. However, these are not routine, safe alternatives to prevent recurrence in asymptomatic patients. They are strictly approved for symptomatic, locally advanced TGCT that causes severe functional limitations and cannot be improved with surgery [21]. Furthermore, these drugs have significant risks; for example, pexidartinib carries a boxed warning for potentially fatal liver toxicity and requires strict liver-function monitoring [22].

Common questions in this guide

Is radiation therapy routinely needed after TGCT surgery?
No. Surgery to remove affected joint lining, called a synovectomy, is the primary treatment, and external-beam radiation is generally reserved for selected cases. It may be discussed when diffuse TGCT is recurrent, incompletely removed, or difficult to control with surgery alone.
Which TGCT cases are most likely to be considered for radiation after surgery?
Doctors may consider radiation when the tumor has returned repeatedly, microscopic tumor remains at a surgical margin, the tumor could not be fully removed because it surrounds important structures, or it extends outside the joint. These features are especially relevant in diffuse TGCT. The decision depends on recurrence risk, symptoms, joint location, and other treatment options.
Can radiation reduce the chance that TGCT comes back?
Radiation aims to improve local control, meaning control of tumor in the treated area. Some observational studies suggest it may reduce recurrence in diffuse TGCT compared with surgery alone, but the evidence is very low quality and results vary. Your team should discuss the possible benefit in absolute numbers for your situation.
What side effects can radiation cause after TGCT surgery?
Radiation can cause skin thickening or color changes and may worsen joint stiffness from scar tissue. Depending on the dose and joint, later effects can include weakened bone, bone death, or fracture; a new radiation-related sarcoma is very rare but serious. Risk also depends on your age, previous surgeries, and the area treated.
What can I do instead of radiation if TGCT remains after surgery?
If a small amount remains but is not causing problems, planned active surveillance may be an option, with regular MRI scans, examinations, and symptom checks. Targeted CSF1R medicines such as pexidartinib or vimseltinib are generally reserved for symptomatic, locally advanced TGCT that cannot be improved with surgery, not routine prevention in people without symptoms. Pexidartinib also requires close liver monitoring because it can cause serious liver injury.
Would a multidisciplinary tumor board help decide about post-surgery radiation?
It may be helpful, especially for diffuse, recurrent, residual, or hard-to-remove TGCT. Orthopedic oncology, radiation oncology, and medical oncology specialists can review the imaging, surgical findings, recurrence risk, and options such as surveillance or targeted therapy together. Ask whether this review is appropriate before starting radiation.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

Pexidartinib vs. Vimseltinib for TGCT: Which Is Right? What Do Hemosiderin and Blooming Mean on a TGCT MRI? Why Is TGCT So Frequently Misdiagnosed as Arthritis? Can Imatinib or Nilotinib Be Used for TGCT Off-Label? Does Joint Replacement Cure TGCT? Recurrence Risks
Show more
Is PVNS the Same Condition as TGCT? Is TGCT a Cancer, and Can It Spread to Other Organs? How Often Do You Need MRI Follow-Up After TGCT Surgery? Can Localized TGCT Turn Into Diffuse TGCT? Explained Why Does Turalio Require a REMS Program for TGCT Treatment? Why See an Orthopedic Oncologist for TGCT Surgery? Open vs Arthroscopic Diffuse TGCT Surgery: Which Is Right? How Does TGCT Damage Cartilage and Bone in the Joint?

Get notified when new evidence is published on Tenosynovial giant cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which type of radiation are you proposing (external-beam or something else), and what is the exact dose and schedule?
  2. 2.Was there evidence from my surgical pathology or post-operative MRI that tumor cells were left behind (a positive margin)?
  3. 3.What is my estimated absolute chance of recurrence with and without radiation therapy?
  4. 4.Should I be evaluated by a multidisciplinary sarcoma tumor board to discuss alternatives like active surveillance before starting radiation?
  5. 5.If we choose active surveillance, what MRI schedule and specific symptoms should trigger treatment?

References

References (22)
  1. 1

    Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective.

    Bernthal NM, Ishmael CR, Burke ZDC

    Current oncology reports 2020; (22(6)):63 doi:10.1007/s11912-020-00926-7.

    PMID: 32494892
  2. 2

    Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.

    Staals EL, Ferrari S, Donati DM, Palmerini E

    European journal of cancer (Oxford, England : 1990) 2016; (63()):34-40.

    PMID: 27267143
  3. 3

    Treatments of tenosynovial giant cell tumours of the temperomandibular joint: a report of three cases and a review of literature.

    Verspoor FGM, Mastboom MJL, Weijs WLJ, et al.

    International journal of oral and maxillofacial surgery 2018; (47(10)):1288-1294 doi:10.1016/j.ijom.2018.04.001.

    PMID: 29709323
  4. 4

    Clinical and immunohistochemical analysis of diffuse tenosynovial giant cell tumour of the temporomandibular joint.

    Wang DD, Luo HY, Guo CB, Meng JH

    International journal of oral and maxillofacial surgery 2020; (49(7)):882-888 doi:10.1016/j.ijom.2019.10.022.

    PMID: 32014315
  5. 5

    Extra-articular diffuse-type tenosynovial giant cell tumor with benign histological features resulting in fatal pulmonary metastases.

    Osanai T, Suzuki H, Hiraga H, et al.

    Journal of orthopaedic surgery (Hong Kong) 2017; (25(1)):2309499017690323 doi:10.1177/2309499017690323.

    PMID: 28219303
  6. 6

    Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study.

    Spierenburg G, Staals EL, Palmerini E, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2024; (50(2)):107953 doi:10.1016/j.ejso.2024.107953.

    PMID: 38215550
  7. 7

    Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.

    Mastboom MJL, Palmerini E, Verspoor FGM, et al.

    The Lancet. Oncology 2019; (20(6)):877-886 doi:10.1016/S1470-2045(19)30100-7.

    PMID: 31029509
  8. 8

    An unusual case of diffuse pigmented villonodular synovitis of the shoulder: A multidisciplinary approach with arthroscopic synovectomy and adjuvant radiotherapy.

    Serra TQ, Morais J, Gonçalves Z, et al.

    European journal of rheumatology 2017; (4(2)):142-144 doi:10.5152/eurjrheum.2016.15084.

    PMID: 28638690
  9. 9

    Pigmented villonodular synovitis of the temporomandibular joint: case report and the literature review for postoperative radiotherapy.

    Yang X, Sun Y, Yu W, Fu J

    Journal of radiology case reports 2019; (13(8)):31-39 doi:10.3941/jrcr.v13i8.3661.

    PMID: 31558968
  10. 10

    What Are the Recurrence Rates, Complications, and Functional Outcomes After Multiportal Arthroscopic Synovectomy for Patients With Knee Diffuse-type Tenosynovial Giant-cell Tumors?

    Yao L, Li Y, Li T, et al.

    Clinical orthopaedics and related research 2024; (482(7)):1218-1229 doi:10.1097/CORR.0000000000002934.

    PMID: 38153106
  11. 11

    The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis.

    Mollon B, Lee A, Busse JW, et al.

    The bone & joint journal 2015; (97-B(4)):550-7 doi:10.1302/0301-620X.97B4.34907.

    PMID: 25820897
  12. 12

    Arthroscopic Synovectomy and Postoperative Assisted Radiotherapy for Treating Diffuse Pigmented Villonodular Synovitis of the Knee: An observational retrospective study.

    Li W, Sun X, Lin J, et al.

    Pakistan journal of medical sciences 2015; (31(4)):956-60 doi:10.12669/pjms.314.7383.

    PMID: 26430437
  13. 13

    Locally Aggressive Connective Tissue Tumors.

    Gounder MM, Thomas DM, Tap WD

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(2)):202-209 doi:10.1200/JCO.2017.75.8482.

    PMID: 29220303
  14. 14

    Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).

    Lingamfelter M, Novaczyk ZB, Cheng EY

    JBJS essential surgical techniques 2022; (12(2)) doi:10.2106/JBJS.ST.21.00035.

    PMID: 36741035
  15. 15

    Patient Outcomes After Resection of Pigmented Villonodular Synovitis in Patients in King Abdulaziz Medical City.

    Aljuhani W, Alamri A, Altorbak B, et al.

    Cureus 2024; (16(8)):e68248 doi:10.7759/cureus.68248.

    PMID: 39347371
  16. 16

    Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee: The role of adjuvant radiotherapy.

    Chien JC, Wei YP, Chen CY, et al.

    Medicine 2021; (100(12)):e23794 doi:10.1097/MD.0000000000023794.

    PMID: 33761628
  17. 17

    Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy.

    Baniel C, Yoo CH, Jiang A, et al.

    Practical radiation oncology 2023; (13(3)):e301-e307 doi:10.1016/j.prro.2022.11.004.

    PMID: 36460182
  18. 18

    Tenosynovial Giant Cell Tumor in the Midfoot Treated With Femoral Head Allograft Reconstruction.

    Fuchs DJ, Switaj PJ, Peabody TD, Kadakia AR

    The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons 2018; (57(1)):172-178 doi:10.1053/j.jfas.2017.07.010.

    PMID: 28864387
  19. 19

    Medical Management of Tenosynovial Giant Cell Tumor.

    Palmerini E, Trent JC, Hornicek FJ

    Current oncology reports 2025; (27(7)):844-855 doi:10.1007/s11912-025-01679-x.

    PMID: 40392406
  20. 20

    Management of tenosynovial giant cell tumor: approved and investigational therapies.

    Conway AP, Lim A, Schulte BC, Agulnik M

    Expert review of anticancer therapy 2026; (26(7)):881-889 doi:10.1080/14737140.2026.2620510.

    PMID: 41557367
  21. 21

    Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.

    Baldi GG, Gronchi A, Stacchiotti S

    Expert review of clinical pharmacology 2020; (13(6)):571-576 doi:10.1080/17512433.2020.1771179.

    PMID: 32478598
  22. 22

    Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.

    Spierenburg G, van der Heijden L, van Langevelde K, et al.

    Expert opinion on therapeutic targets 2022; (26(4)):333-345 doi:10.1080/14728222.2022.2067040.

    PMID: 35443852

This page is for informational purposes only and does not constitute medical advice. Your orthopedic and oncology team can help weigh recurrence risk, joint function, and alternatives to radiation after TGCT surgery.